한글목차

개요

BRAF 키나아제 억제제 시장은 2023-2028년간 14억 달러 확대되고, 예측 기간 중 연평균 복합 성장률(CAGR)은 7.88%를 나타낼 것으로 예측됩니다.

BRAF 키나아제 억제제 시장에 대한 전체적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 대상으로 한 벤더 분석 등의 정보를 게재했습니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공합니다. BRAF 키나아제 억제제의 높은 표적 친화성과 특이성, 환자 지원 프로그램의 존재, 암 유병률 증가 등에 의해 시장 성장이 가속되고 있습니다.

본 조사에서는 향후 몇 년간 BRAF 키나아제 억제제 시장 성장을 가속하는 주요인 중 하나로서 BRAF 키나아제 억제제의 연구 영역 확대를 들고 있습니다. 또한 전략적 제휴 확대나 암에 대한 의식 고양 또한 이 시장의 높은 수요로 연결될 전망입니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 생태계

제3장 시장 규모

• 시장의 정의
• 시장 부문 분석
• 시장 규모(2023년)
• 시장 전망(2023-2028년)

제4장 시장 규모 실적

• 세계의 BRAF 키나아제 억제제 시장(2018-2022년)
• 제품별 부문 분석(2018-2022년)
• 유형별 부문 분석(2018-2022년)
• 지역별 부문 분석(2018-2022년)
• 국가별 부문 분석(2018-2022년)

제5장 Five Forces 분석

• Five Forces 요약
• 바이어의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁 위협
• 시장 현황

제6장 시장 세분화 : 제품별

• 시장 부문
• 비교 : 제품별
• Dabrafenib : 시장 규모와 예측(2023-2028년)
• Sorafenib : 시장 규모와 예측(2023-2028년)
• Vemurafenib : 시장 규모와 예측(2023-2028년)
• Encorafenib : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 제품별

제7장 시장 세분화 : 유통 채널별

• 시장 부문
• 비교 : 유통 채널별
• 병원 약국 : 시장 규모와 예측(2023-2028년)
• 소매 약국 : 시장 규모와 예측(2023-2028년)
• 온라인 약국 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 유통 채널별

제8장 고객 상황

• 고객 상황 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측(2023-2028년)
• 유럽 : 시장 규모와 예측(2023-2028년)
• 아시아 : 시장 규모와 예측(2023-2028년)
• 세계 기타 지역 : 시장 규모와 예측(2023-2028년)
• 미국 : 시장 규모와 예측(2023-2028년)
• 독일 : 시장 규모와 예측(2023-2028년)
• 영국 : 시장 규모와 예측(2023-2028년)
• 프랑스 : 시장 규모와 예측(2023-2028년)
• 일본 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 지역 상황별

제10장 성장 촉진요인, 과제 및 동향

• 시장 성장 촉진요인
• 시장이 해결해야 할 과제
• 성장 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란 상황
• 업계 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• Asana BioSciences LLC
• Bayer AG
• BeiGene Ltd.
• Black Diamond Therapeutics Inc.
• F. Hoffmann La Roche Ltd.
• Fore Biotherapeutics Inc.
• Jazz Pharmaceuticals Plc
• Kinnate Biopharma
• Nerviano Medical Sciences S.r.l
• Novartis AG
• Ono Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Pierre Fabre SA

제13장 부록

영문목차

Abstract

The BRAF kinase inhibitors market is forecasted to grow by USD 1.40 bn during 2023-2028, accelerating at a CAGR of 7.88% during the forecast period. The report on the BRAF kinase inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the high target affinity and specificity of BRAF kinase inhibitors, the presence of patient assistance programs, and the increasing prevalence of cancer.

Technavio's BRAF kinase inhibitors market is segmented as below:

By Product

• Dabrafenib
• Sorafenib
• Vemurafenib
• Encorafenib

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the expansion of research areas in BRAF kinase inhibitors as one of the prime reasons driving the BRAF kinase inhibitors market growth during the next few years. Also, growing strategic alliances and growing awareness of cancer will lead to sizable demand in the market.

The report on the BRAF kinase inhibitors market covers the following areas:

• Braf kinase inhibitors market sizing
• Braf kinase inhibitors market forecast
• Braf kinase inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading BRAF kinase inhibitors market vendors that include Asana BioSciences LLC, Bayer AG, BeiGene Ltd., F. Hoffmann La Roche Ltd., Fore Biotherapeutics Inc., Jazz Pharmaceuticals Plc, Nerviano Medical Sciences S.r.l, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Pierre Fabre SA, Kinnate Biopharma, and Black Diamond Therapeutics Inc.. Also, the BRAF kinase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global BRAF kinase inhibitors market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global braf kinase inhibitors market 2018 - 2022 ($ billion)
• 4.2 Product Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
• 4.3 Type Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

• 6.1 Market segments
• Exhibit 30: Chart on Product - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
• 6.2 Comparison by Product
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product
• 6.3 Dabrafenib - Market size and forecast 2023-2028
• Exhibit 34: Chart on Dabrafenib - Market size and forecast 2023-2028 ($ billion)
• Exhibit 35: Data Table on Dabrafenib - Market size and forecast 2023-2028 ($ billion)
• Exhibit 36: Chart on Dabrafenib - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Dabrafenib - Year-over-year growth 2023-2028 (%)
• 6.4 Sorafenib - Market size and forecast 2023-2028
• Exhibit 38: Chart on Sorafenib - Market size and forecast 2023-2028 ($ billion)
• Exhibit 39: Data Table on Sorafenib - Market size and forecast 2023-2028 ($ billion)
• Exhibit 40: Chart on Sorafenib - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Sorafenib - Year-over-year growth 2023-2028 (%)
• 6.5 Vemurafenib - Market size and forecast 2023-2028
• Exhibit 42: Chart on Vemurafenib - Market size and forecast 2023-2028 ($ billion)
• Exhibit 43: Data Table on Vemurafenib - Market size and forecast 2023-2028 ($ billion)
• Exhibit 44: Chart on Vemurafenib - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Vemurafenib - Year-over-year growth 2023-2028 (%)
• 6.6 Encorafenib - Market size and forecast 2023-2028
• Exhibit 46: Chart on Encorafenib - Market size and forecast 2023-2028 ($ billion)
• Exhibit 47: Data Table on Encorafenib - Market size and forecast 2023-2028 ($ billion)
• Exhibit 48: Chart on Encorafenib - Year-over-year growth 2023-2028 (%)
• Exhibit 49: Data Table on Encorafenib - Year-over-year growth 2023-2028 (%)
• 6.7 Market opportunity by Product
• Exhibit 50: Market opportunity by Product ($ billion)
• Exhibit 51: Data Table on Market opportunity by Product ($ billion)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments
• Exhibit 52: Chart on Distribution Channel - Market share 2023-2028 (%)
• Exhibit 53: Data Table on Distribution Channel - Market share 2023-2028 (%)
• 7.2 Comparison by Distribution Channel
• Exhibit 54: Chart on Comparison by Distribution Channel
• Exhibit 55: Data Table on Comparison by Distribution Channel
• 7.3 Hospital pharmacies - Market size and forecast 2023-2028
• Exhibit 56: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
• Exhibit 57: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
• Exhibit 58: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• 7.4 Retail pharmacies - Market size and forecast 2023-2028
• Exhibit 60: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
• Exhibit 61: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
• Exhibit 62: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 63: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• 7.5 Online pharmacies - Market size and forecast 2023-2028
• Exhibit 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
• Exhibit 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
• Exhibit 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by Distribution Channel
• Exhibit 68: Market opportunity by Distribution Channel ($ billion)
• Exhibit 69: Data Table on Market opportunity by Distribution Channel ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 73: Chart on Geographic comparison
• Exhibit 74: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Germany - Market size and forecast 2023-2028
• Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.9 UK - Market size and forecast 2023-2028
• Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.10 France - Market size and forecast 2023-2028
• Exhibit 103: Chart on France - Market size and forecast 2023-2028 ($ billion)
• Exhibit 104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
• Exhibit 105: Chart on France - Year-over-year growth 2023-2028 (%)
• Exhibit 106: Data Table on France - Year-over-year growth 2023-2028 (%)
• 9.11 Japan - Market size and forecast 2023-2028
• Exhibit 107: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibit 108: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibit 109: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibit 110: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 111: Market opportunity By Geographical Landscape ($ billion)
• Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 113: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 115: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 116: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 117: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 118: Matrix on vendor position and classification
• 12.3 Asana BioSciences LLC
• Exhibit 119: Asana BioSciences LLC - Overview
• Exhibit 120: Asana BioSciences LLC - Product / Service
• Exhibit 121: Asana BioSciences LLC - Key offerings
• 12.4 Bayer AG
• Exhibit 122: Bayer AG - Overview
• Exhibit 123: Bayer AG - Business segments
• Exhibit 124: Bayer AG - Key news
• Exhibit 125: Bayer AG - Key offerings
• Exhibit 126: Bayer AG - Segment focus
• 12.5 BeiGene Ltd.
• Exhibit 127: BeiGene Ltd. - Overview
• Exhibit 128: BeiGene Ltd. - Business segments
• Exhibit 129: BeiGene Ltd. - Key offerings
• Exhibit 130: BeiGene Ltd. - Segment focus
• 12.6 Black Diamond Therapeutics Inc.
• Exhibit 131: Black Diamond Therapeutics Inc. - Overview
• Exhibit 132: Black Diamond Therapeutics Inc. - Product / Service
• Exhibit 133: Black Diamond Therapeutics Inc. - Key offerings
• 12.7 F. Hoffmann La Roche Ltd.
• Exhibit 134: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 135: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 136: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 137: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 138: F. Hoffmann La Roche Ltd. - Segment focus
• 12.8 Fore Biotherapeutics Inc.
• Exhibit 139: Fore Biotherapeutics Inc. - Overview
• Exhibit 140: Fore Biotherapeutics Inc. - Product / Service
• Exhibit 141: Fore Biotherapeutics Inc. - Key offerings
• 12.9 Jazz Pharmaceuticals Plc
• Exhibit 142: Jazz Pharmaceuticals Plc - Overview
• Exhibit 143: Jazz Pharmaceuticals Plc - Product / Service
• Exhibit 144: Jazz Pharmaceuticals Plc - Key news
• Exhibit 145: Jazz Pharmaceuticals Plc - Key offerings
• 12.10 Kinnate Biopharma
• Exhibit 146: Kinnate Biopharma - Overview
• Exhibit 147: Kinnate Biopharma - Product / Service
• Exhibit 148: Kinnate Biopharma - Key offerings
• 12.11 Nerviano Medical Sciences S.r.l
• Exhibit 149: Nerviano Medical Sciences S.r.l - Overview
• Exhibit 150: Nerviano Medical Sciences S.r.l - Product / Service
• Exhibit 151: Nerviano Medical Sciences S.r.l - Key offerings
• 12.12 Novartis AG
• Exhibit 152: Novartis AG - Overview
• Exhibit 153: Novartis AG - Business segments
• Exhibit 154: Novartis AG - Key offerings
• Exhibit 155: Novartis AG - Segment focus
• 12.13 Ono Pharmaceutical Co. Ltd.
• Exhibit 156: Ono Pharmaceutical Co. Ltd. - Overview
• Exhibit 157: Ono Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 158: Ono Pharmaceutical Co. Ltd. - Key offerings
• 12.14 Pfizer Inc.
• Exhibit 159: Pfizer Inc. - Overview
• Exhibit 160: Pfizer Inc. - Product / Service
• Exhibit 161: Pfizer Inc. - Key news
• Exhibit 162: Pfizer Inc. - Key offerings
• 12.15 Pierre Fabre SA
• Exhibit 163: Pierre Fabre SA - Overview
• Exhibit 164: Pierre Fabre SA - Business segments
• Exhibit 165: Pierre Fabre SA - Key offerings
• Exhibit 166: Pierre Fabre SA - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 167: Inclusions checklist
• Exhibit 168: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 169: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 170: Research methodology
• Exhibit 171: Validation techniques employed for market sizing
• Exhibit 172: Information sources
• 13.5 List of abbreviations
• Exhibit 173: List of abbreviations